Drugs / CervarixTM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT01418937 | May 2012 → Jan 2015 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00996125 | Oct 2009 → Dec 2010 | human papilloma virus infection | GlaxoSmithKline | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00359619 Comparator | Sep 2006 → Jan 2007 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CervarixTM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01418937 ↗ |
| Modality | Vaccine | “HPV-16/18 AS04-adjuvanted vaccine” PMID 25424785 ↗ 2014 |
| Route | Intramuscular | “The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.” NCT00359619 ↗ |